Our website publishes news, press releases, opinion and advertorials on various financial organizations, products and services which are commissioned from various Companies, Organizations, PR agencies, Bloggers etc. These commissioned articles are commercial in nature. This is not to be considered as financial advice and should be considered only for information purposes. It does not reflect the views or opinion of our website and is not to be considered an endorsement or a recommendation. We cannot guarantee the accuracy or applicability of any information provided with respect to your individual or personal circumstances. Please seek Professional advice from a qualified professional before making any financial decisions. We link to various third-party websites, affiliate sales networks, and to our advertising partners websites. When you view or click on certain links available on our articles, our partners may compensate us for displaying the content to you or make a purchase or fill a form. This will not incur any additional charges to you. To make things simpler for you to identity or distinguish advertised or sponsored articles or links, you may consider all articles or links hosted on our site as a commercial article placement. We will not be responsible for any loss you may suffer as a result of any omission or inaccuracy on the website.
FILE PHOTO: Products produced by Reckitt Benckiser are seen in London, Britain, February 12, 2008. REUTERS/Stephen Hird

Reckitt lifts full-year forecast as mobility, vaccinations pick up

By Siddharth Cavale

(Reuters) – Higher vaccination rates and improved mobility during the third quarter drove strong demand for Mucinex cough syrups and Durex condoms, Reckitt Benckiser Group said on Tuesday, prompting it to raise its full-year forecast.

That sent its shares up 5.8% in morning trading, making it the top gainer on the FTSE index.

Sales of over-the-counter medicines rose more than 20% in the quarter, driven primarily by Mucinex cough and cold remedies after a strong cold and flu season saw sales across most of its markets come in at or above 2019 levels, it said.

Improved mobility in markets including India also saw the company gain share in sexual wellness products such as Durex, Chief Executive Laxman Narasimhan said on a media call.

That drove like-for-like sales up 3.3% in the quarter, compared to the 0.7% drop analysts had expected, according to company-supplied estimates, which excluded sales from the recently completed sale of its infant nutrition business in China.

The company also raised its full-year net revenue like-for-like growth forecast to 1-3% from flat to 2% earlier, but cautioned that growth would be “softer” in the fourth quarter.

Don't miss out on any breaking news or insightful opinions!
Subscribe to our free newsletter and stay updated on the go!

By submitting this form, you are consenting to receive marketing emails from: Global Banking and Finance Review, Alpha House, Greater London, SE1 1LB, https://www.globalbankingandfinance.com/. You can revoke your consent to receive emails at any time by using the SafeUnsubscribe® link, found at the bottom of every email. Emails are serviced by Constant Contact

Like its peers, Reckitt said it was seeing a sharp rise in raw materials costs, which were up 10% in the quarter compared with an 8-9% rise it had estimated previously.

Chief Financial Officer Jeff Carr said he expected inflation to be “up a touch” in the fourth quarter and possibly in the low double digits in 2022, but could not estimate when these higher costs would subside.

“There will be another round of pricing we will take to offset the inflation,” Narasimhan said, over and above the 1.7% hikes it took in the third quarter.

Domestos maker Unilever last week also warned of another round of price hikes to battle fierce inflation.

Reckitt kept its adjusted operating profit margin forecast, excluding IFCN China, for the year in the range of 22.7% to 23.2%

Shares in the group were down 16% this year before the results, after hitting near-record levels in 2020.

(Reporting by Siddharth Cavale in Bengaluru; Editing by Anil D’Silva and Jan Harvey)

Recent Post: